Decarboxylated Carnosine: A Promising Active Ingredient for Anti-Glycation and Antioxidant Skincare
Publish Time:
2026-10-22
Discover the Potential of Decarboxylated Carnosine for Advanced Skin Aging Care
As the skincare industry continues to explore innovative solutions for skin aging, anti-glycation and antioxidant ingredients are attracting growing attention. Decarboxylated Carnosine is a promising active ingredient for advanced skincare formulations, offering potential benefits in addressing oxidative stress and glycation-related skin aging.
At CongenPharma, we focus on the development and supply of specialty cosmetic active ingredients to support innovative skincare formulations.
What Is Decarboxylated Carnosine?
Decarboxylated Carnosine is a carnosine-related compound of interest in cosmetic ingredient research. It is relevant to the development of skincare formulations targeting oxidative stress and the visible signs of skin aging.
Glycation occurs when reducing sugars react with proteins, potentially contributing to the formation of advanced glycation end products (AGEs). In the skin, glycation-related changes may affect collagen and elastin, contributing to reduced skin elasticity, a less even appearance, and visible signs of aging.
Antioxidant skincare ingredients, meanwhile, are used to help protect the skin against oxidative stress associated with environmental exposure and other aging-related factors.
Key Benefits for Anti-Aging Skincare
1. Anti-Glycation Potential
Glycation is an important research area in skin aging. Ingredients investigated for their effects on glycation pathways may offer opportunities for developing skincare products designed to help maintain the appearance and quality of aging skin.
2. Antioxidant Potential
Oxidative stress is associated with skin aging and environmental damage. Antioxidant-oriented ingredients can be incorporated into skincare research and formulation development to support skin protection strategies.
3. Support for Advanced Anti-Aging Formulations
With increasing interest in multifunctional cosmetic actives, Decarboxylated Carnosine may be considered for research into formulations targeting visible signs of skin aging, skin firmness, and overall skin appearance, subject to ingredient-specific efficacy and compatibility data.
Why Choose CongenPharma?
Guangzhou Congen Pharmatec Co., Ltd. (CongenPharma) is a specialty ingredient manufacturer established in 2013, with experience in cosmetic active ingredients, peptides, and pharmaceutical intermediates.
Our capabilities include:
- Specialty Ingredient Development: Supporting the development of differentiated active ingredients for cosmetic applications.
- R&D and Pilot Facilities: More than 2,000 m² of R&D and pilot-scale laboratory space.
- Quality Management: An ISO 9001:2015 quality management system.
- Technical Support: Product information and technical documentation available according to the ingredient and project requirements.
We follow applicable quality and technical requirements to support reliable ingredient supply and customer formulation development.
CG Brightin® Decarboxylated Carnosine Hydrochloride
Product Specifications
CG Brightin® is CongenPharma's branded Decarboxylated Carnosine Hydrochloride, developed for cosmetic formulations exploring anti-glycation, antioxidant, and skin-aging care applications.
| Parameter | Specification |
|---|---|
| Trade Name | CG Brightin® |
| Common Name | Decarboxylated Carnosine HCl |
| Chinese INCI Name | 脱羧肌肽盐酸盐 |
| English INCI Name (as provided) | Decarboxy Carnosine Hydrochloride |
| CAS Number | 57022-38-5 |
| Appearance | White to off-white powder |
| Solubility | Water-soluble |
| pH | 2.5–4.5 |
| Purity | Standard: ≥98.5%; Actual test result: 99.6% |
| Recommended Use Level | 0.05–1.5% |
Formulation Applications
CG Brightin® can be evaluated for use in anti-aging skincare formulations, including products designed around anti-glycation and antioxidant concepts. Its water solubility offers formulation flexibility for compatible aqueous systems.
The recommended use level is 0.05–1.5%. Final concentration should be determined according to formulation compatibility, stability testing, safety assessment, and substantiated efficacy data.
Contact CongenPharma
Contact CongenPharma for product specifications, technical documentation, sample availability, and formulation-related enquiries.
Relevant Information
undefined
